{"entity":{"id":"nct03899792","kind":"trial","name":"A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors","aka":[],"tldr":"A phase 1/2 trial of Selpercatinib in thyroid cancer and sarcomas, run by Eli Lilly and Company, active and no longer recruiting.","summary":"A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors is a phase 1/2 interventional study registered as NCT03899792 by Eli Lilly and Company, with 36 participants enrolled, started 2019-06-13 and due to reach its primary completion in 2024-11-08. Interventions recorded: Selpercatinib. Conditions listed: Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03899792","url":"https://clinicaltrials.gov/study/NCT03899792"}],"tags":["ctgov-ingest"],"related":[],"cancers":["thyroid","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":["selpercatinib"],"companies":["eli-lilly"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03899792","phase":"1/2","setting":"A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors","sponsor":"Eli Lilly and Company","enrolled":36,"outcomes":[]},"route":"/trials/nct03899792/","neighbours":{"cancer":[{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"},{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/"}],"drug":[{"id":"selpercatinib","kind":"drug","name":"Selpercatinib","route":"/drugs/selpercatinib/"}],"company":[{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/"}]}}